Tryptophan metabolism in health and disease

C Xue, G Li, Q Zheng, X Gu, Q Shi, Y Su, Q Chu… - Cell Metabolism, 2023 - cell.com
Tryptophan (Trp) metabolism primarily involves the kynurenine, 5-hydroxytryptamine, and
indole pathways. A variety of bioactive compounds produced via Trp metabolism can …

The footprint of kynurenine pathway in every cancer: a new target for chemotherapy

M Ala - European Journal of Pharmacology, 2021 - Elsevier
Abstract Treatment of cancers has always been a challenge for physicians. Typically,
several groups of anti-cancer medications are needed for effective management of an …

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape …

C Krupka, P Kufer, R Kischel, G Zugmaier… - Leukemia, 2016 - nature.com
Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells. We
tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute …

[HTML][HTML] Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis

PA Zunszain, C Anacker, A Cattaneo… - …, 2012 - nature.com
Increased inflammation and reduced neurogenesis have been associated with the
pathophysiology of major depression. Here, we show for the first time how IL-1β, a pro …

Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets

M Stahl, AD Goldberg - Current oncology reports, 2019 - Springer
Abstract Purpose of Review Immune checkpoint therapy has dramatically changed the
therapeutic landscape of solid malignancies. Here, we review the scientific rationale and …

[HTML][HTML] Indoleamine 2, 3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia

V Folgiero, BM Goffredo, P Filippini, R Masetti… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Microenvironmental factors contribute to the immune dysfunction characterizing acute
myeloid leukemia (AML). Indoleamine 2, 3-dioxygenase 1 (IDO1) is an interferon (IFN)-γ …

Harnessing the immune system in acute myeloid leukaemia

R Austin, MJ Smyth, SW Lane - Critical reviews in oncology/hematology, 2016 - Elsevier
Acute myeloid leukaemia (AML) is an aggressive blood cancer caused by the proliferation of
immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction …

Interferon‐induced programmed death‐ligand 1 (PD‐L 1/B 7‐H 1) expression increases on human acute myeloid leukemia blast cells during treatment

H Krönig, L Kremmler, B Haller… - European journal of …, 2014 - Wiley Online Library
Introduction While current treatment for acute myeloid leukemia is characterized by high
response rates, patients' long‐term outcome is still disappointing, due to frequent relapse …

[HTML][HTML] Mesenchymal stem and progenitor cells in normal and dysplastic hematopoiesis—masters of survival and clonality?

L Pleyer, P Valent, R Greil - International journal of molecular sciences, 2016 - mdpi.com
Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders that
have the capacity to progress to acute myeloid leukemia (AML). Accumulating evidence …

Metabolic regulation of the bone marrow microenvironment in leukemia

B Xu, R Hu, Z Liang, T Chen, J Chen, Y Hu, Y Jiang… - Blood Reviews, 2021 - Elsevier
Most leukemia patients experience little benefit from immunotherapy, in part due to the
immunosuppressive bone marrow microenvironment. Various metabolic mechanisms …